6 reports

  • 4.3 GRANULOCYTE - COLONY STIMULATING FACTOR (G-CSF) BIOSIMILARS MARKET

This year, the wholly owned subsidiary cell pharm launched the filgrastim product Grastrofil.

  • G-CSF
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Market drivers
  • Neutropenia market in EMEA

The drug contains tbo-filgrastim as its main API.

  • G-CSF
  • Europe
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • FILGRASTIM - DRUG PROFILE
  • G-CSF
  • Therapy
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 8 Trial Title
  • Clinical Trial profile. 30 Trial Title
  • Blood Disease
  • Blood Supply
  • G-CSF
  • World
  • Product Initiative

Granulocyte Colony Page## BLOOD DISEASE DRUGS PRODUCER DIRECTORY stimulating Factor (Filgrastim, rHuG-CSF) and Interleukin ##(rHuIL-##), etc.

  • G-CSF
  • China
  • Demand
  • Market Size
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Filgrastim: Biosimilar Products in Other Less Regulated Markets
  • Filgrastim: Biosimilar Products in China & Taiwan - 2/2
  • Filgrastim
  • G-CSF
  • Europe
  • United States
  • Amgen Inc.